Biogen (BIIB) PT Raised to $367 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
August 1, 2016 7:30 AM EDTBiogen Intends to File Marketing Applications for Nusinersen with Regulatory Authorities in the Coming Months
Biogen Exercises Option to Develop and Commercialize Nusinersen Globally
Companies to Host Webcast Today at 9:00 a.m. EDT to Provide Program Update
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)-- Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS) today announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in... More
